Non-alcoholic steatohepatitis

17 clinical trials

Quick filters

Clinical trials for Non-alcoholic steatohepatitis

17 trials across Europe

See all trials →

Quick filters

17 Clinical trials

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

Investigational

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

Investigational

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Hepatic fibrosis+2

Recruiting

Investigational

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Efruxifermin
Sponsor:Akero Therapeutics Inc.

Contact Research Centre

Hepatic cirrhosis+2

Recruiting

Investigational

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Efruxifermin
Sponsor:Akero Therapeutics Inc.

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

Investigational

Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Namodenoson
Sponsor:Can-Fite Biopharma Ltd.

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Not yet recruiting

Investigational

Study of Fecal Microbiota Capsules for Treating Non-Alcoholic Steatohepatitis in Patients

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Allogeneic Faecal Microbiota, Pooled
Sponsor:Mikrobiomik Healthcare Company S.L.

Contact Research Centre

See all trials →

Non-alcoholic steatohepatitis

Clinical trials for Non-alcoholic steatohepatitis

Metabolic dysfunction-associated steatohepatitis+1

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Metabolic dysfunction-associated steatohepatitis+1

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Hepatic fibrosis+2

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Hepatic cirrhosis+2

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Metabolic dysfunction-associated steatohepatitis+1

Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis+1

Study of Fecal Microbiota Capsules for Treating Non-Alcoholic Steatohepatitis in Patients

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.

Non-alcoholic steatohepatitis

Clinical trials for Non-alcoholic steatohepatitis

Metabolic dysfunction-associated steatohepatitis+1

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Metabolic dysfunction-associated steatohepatitis+1

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Hepatic fibrosis+2

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Hepatic cirrhosis+2

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Metabolic dysfunction-associated steatohepatitis+1

Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis+1

Study of Fecal Microbiota Capsules for Treating Non-Alcoholic Steatohepatitis in Patients

Prefer not to search? Our Concierge searches the trials for you.

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis